VDX-431
Triple-Negative Breast Cancer (TNBC), Ovarian Cancer, Melanoma
Pre-clinicalActive
Key Facts
Indication
Triple-Negative Breast Cancer (TNBC), Ovarian Cancer, Melanoma
Phase
Pre-clinical
Status
Active
Company
About Vona Oncology
Vona Oncology is a private, pre-revenue biotech founded in 2018, developing VDX-431, a novel small molecule drug targeting aggressive cancers like TNBC, ovarian cancer, and melanoma. The company has raised $3.3 million in non-dilutive funding, primarily from government grants, and is currently in the pre-clinical stage, working towards an IND submission. Its strategy is to demonstrate early clinical efficacy in TNBC and leverage compelling pre-clinical data showing tumor growth inhibition and synergy with chemotherapy. Vona's long-term vision is to evolve into a discovery and development company translating novel cancer biology insights into clinical treatments.
View full company profile